Completed PHASE2 INTERVENTIONAL NCT00193544

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma

Sponsor: CTI BioPharma

Interventions Arsenic Trioxide Thalidomide

Updated 5 times since 2017 Last updated: Jan 21, 2009 Started: Mar 31, 2002 Primary completion: Oct 31, 2005 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00193544, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by CTI BioPharma, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CTI BioPharma
SCRI Development Innovations, LLC

Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.